Indication

Unresectable Digestive System Neuroendocrine Carcinoma

1 clinical trial

3 drugs

Clinical trial

Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin

Status: Active (not recruiting), Estimated PCD: 2022-10-18

Drug

Drug

Drug

Liposomal Irinotecan